EGFR and non-small cell lung carcinoma: However, given that the marked gap in the health outcome for patients with EGFR-mutation-positive NSCLC still exists and the availability of more effective treatment options, the next critical question to address is whether more effective treatment (i.e., dacomitinib) represents value-for-money, in other words, whether the increased benefits justify the increased costs.